Additional Ongoing and Planned Clinical Studies:
Treovir has an aggressive plan to test G207 clinically in multiple pediatric indications over the next 3 years:
Recurrent Medulloblastoma - Phase 1. G207 therapy in combination with 5Gy Radiation
For more information go to: NCT# 03911388
Recurrent Glioblastoma - Phase 2. G207 with 5Gy Radiation: - anticipated start 2020. Designed to demonstrate therapeutic efficacy with power to support product approval.
Pediatric: Combination Therapy Trials - Phase 1.
G207, 5Gy radiation with 1 vs 2 Checkpoint Inhibitors: Phase 1
G207, 5Gy radiation with low dose temozolomide: Phase 1
Newly Diagnosed Pediatric Patients - Phase 1.
Glioblastoma: G207 + 5Gy radiation; 3 week pause then 2Gy radiation attenuated fractions (15 instead of 30) with concurrent low dose temozolomide (70mg/M2)
Medulloblastoma - G207 therapy in combination with 5Gy Radiation
Future Adult Trial: Low Grade Glioma Phase 1.
G207 with 5 Gy Radiation with or without checkpoint inhibitors